Assessing the cost-effectiveness of pharmacogenomics

AAPS Journal

Volumn 2, Issue 3, 2000, Pages

  Veenstra, David L ^a   Higashi, Mitchell K ^b   Phillips, Kathryn A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CARRIER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEINS; HYPOCHOLESTEROLEMIC AGENT; INTERFERON; MERCAPTOPURINE; METHYLTRANSFERASE; PRAVASTATIN; RIBAVIRIN; THIOPURINE METHYLTRANSFERASE; WARFARIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CLINICAL PHARMACOLOGY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS; ENZYMOLOGY; GENETICS; GENOTYPE; HEPATITIS C; HUMAN; METHODOLOGY; NUTRITIONAL DEFICIENCY; PHARMACOGENETICS; PHENOTYPE;

6-MERCAPTOPURINE; ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; ANTIMETABOLITES, ANTINEOPLASTIC; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CHILD; COMPARATIVE STUDY; COST-BENEFIT ANALYSIS; DRUG THERAPY; GENOTYPE; HEPATITIS C; HUMAN; INTERFERONS; LEUKEMIA, LYMPHOCYTIC, ACUTE; METHYLTRANSFERASES; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; PHENOTYPE; PRAVASTATIN; RIBAVIRIN; WARFARIN;

EID: 18044400330     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps020329     Document Type: Article

References (44)

1. Collins FS. Genetics: An explosion of knowledge is transforming clinical practice. Geriatrics. 1999;54:41-47.
2. Friend SH. How DNA microarrays and expression profiling will affect clinical practice. BMJ. 1999;319:l-2.
3. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
4. Brookes AJ. The essence of SNPs. Gene. 1999;234:177-186.
5. Gelehrter TD, Collins FS, Ginsburg D. Principles of Medical Genetics. 2nd ed. Baltimore, Md: Williams & Wilkins; 1998.
6. McCarthy JJ, Hilfiker R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol. 2000; 18:505-508.
7. Veenstra DL, Kollman PA. Modeling protein stability: a theoretical analysis of the stability of T4 lysozyme mutants. Protein Eng. 1997; 10:789-807.
8. Sadee W. Pharmacogenomics.BMJ. 1999;319:M.
9. Marshall A. Getting the right drug into the right patient. Nat Biotechnol. 1997; 15:1249-1252.
10. Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Sconce. 1998;281:1820-1821.
11. Hodgson J, Marshall A. Pharmacogenomics: will the regulators approve? Nat Biotechnol. 1998;16:243-246.
12. Regalado A. Inventing the pharmacogenomics business. Am J Health Syst Pharm. 1999;56:40-50.
13. Persidis A. The business of pharmacogenomics. Nat Biotechnol 1998; 16:209-210.
14. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1-31.
15. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
16. Drummond M, Dubois D, Garattini L, et al. Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value in Health. 1999;2:323-332.
17. CCOHTA. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluations of pharmaceuticals: Canada. 2nd ed.; 1997 (http://www.ccohta.ca/main-e.html).
18. Mather DB, Sullivan SD, Augenstein D, Fullerton DS, Athlerly D. Incorporating clinical outcomes and economic consequences into drug formulary decisions: a practical approach. Am J Manag Care. 1999;5:277-285.
19. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijf P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. NEnglJ Med. 1998;338:86-93.
20. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustigi VK, Goodman ZD, Ling M, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination withribavirin as initial treatment for chronic hepatitis C. NEnglJ Med. 1998;339(21):1485-1492.
21. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Costeffectiveness of Interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30(5):1318-1324.
22. Veenstra DL, Tran C, Lum B, Cheung R. The cost-effectiveness of genetic screening and combination therapy for hepatitis C. Paper presented at: Drug Information Association 2nd Annual Workshop on Pharmaceutical Outcomes Research; May 11-12, 2000; Seattle, Wash.
23. Weinstein MC, Goldie SJ, Cohen C, Losina H, Zhang HJ, Kimmel AD. Resistance testing to guide the choice of second-line antiretroviral therapy in HJV: clinical impact and cost-effectiveness [abstract]. In: Program and Abstracts of the Meeting of the Society for Medical Decision Making; October 3-6, 1999; Reno, Nev.
24. Anis AH, Wang X, Harrigan R, Hogg RS, Yin B, O'Shaghnessy MV, Schlechter MT, Montaner JSG. Optimizing drug treatment: cost-effectiveness analysis of HJV/AIDS drug resistance testing [abstract]. In: Program and Abstracts of the Meeting of the Society for Medical Decision Making; October 3-6, 1999; Reno, Nev.
25. Shak S and the Herceptin Multinational Investigator Study Group. Overview of the trastuzumab Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast
26. Motulsky AG. Drug reactions, enzymes and biochemical genetics. JAMA. 1957; 165:835-837.
27. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994;4:39-42.
28. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719.
29. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Phann Res. 1999;16(3):342-349.
30. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991;119:985-989.
31. Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1993;69:577-579.
32. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989;46:149-154.
33. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1-Getting started. Med Decis Making. 1997;17:123-125.
34. Steinbach G, Lynch PM, Phillips RKS. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N EnglJMed. 2000;342:1946-1952.
35. Perrin L, Telenti A. HTV treatment failure: testing for HTV resistance in clinical practice. Science. 1998;280:1871 -1873.
36. Richman DD. Principles of HW resistance testing and overview of assay performance characteristics. Antivir Ther. 2000;5:27-31.
37. Liggett SB. Pharmacogenetics of relevant targets in asthma. Clin Exp Allergy. 1998;28(suppl l):77-79.
38. Israel E, Drazen JM, Ligget SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am JRespir Crit Care Med 2000; 162:75-80.
39. Richard F, Helbecque N, Neuman E, Guez D, Levy R, Amouyel P. APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet. 1997;349:539.
40. Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann N YAcadSci. 1996;802:101-110.
41. Jonsson EG, Nothen MM, Gustavsson JP, Neidt H, Bunzel R, Propping P, Sedvall GC. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res. 1998;79:l-9.
42. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999;282:790-795.
43. Lichter JB, Kurth JH. The impact of pharmacogenetics on the future
44. Rioux PP. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am J Health Syst Pharm. 2000;57:887-898.